Rapid decrease in delivery of chemotherapy to tumors after anti-vegf therapy: Implications for scheduling of anti-angiogenic drugs

Cancer Cell

Volumn 21, Issue 1, 2012, Pages 82-91

  VanderVeldt, AstridA M ^a   Lubberink, Mark ^a,b   Bahce, Idris ^a   Walraven, Maudy ^a   deBoer, Michiel P ^a   Greuter, Henri N J M ^a   Hendrikse, N Harry ^a   Eriksson, Jonas ^a   Windhorst, Albert D ^a   Postmus, Pieter E ^a   Verheul, Henk M ^a   Serné, Erik H ^a   Lammertsma, Adriaan A ^a   Smit, Egbert F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBON 11; DOCETAXEL; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER PATIENT; CAPILLARY DENSITY; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIASTOLIC BLOOD PRESSURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EXPOSURE; DRUG UPTAKE; FEMALE; HUMAN; HYPERTENSION; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THYROID GLAND; TUMOR VASCULARIZATION;

EID: 84855931910     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.11.023     Document Type: Article

References (49)

1. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
2. Boellaard R., Knaapen P., Rijbroek A., Luurtsema G.J., Lammertsma A.A. Evaluation of basis function and linear least squares methods for generating parametric blood flow images using 15O-water and Positron Emission Tomography. Mol. Imaging Biol. 2005, 7:273-285.
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6:389-395.
4. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009, 6:465-477.
5. Cobleigh M.A., Langmuir V.K., Sledge G.W., Miller K.D., Haney L., Novotny W.F., Reimann J.D., Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. 2003, 30(Suppl 16):117-124.
6. Curti B.D., Urba W.J., Alvord W.G., Janik J.E., Smith J.W., Madara K., Longo D.L. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 1993, 53(Suppl):2204-2207.
7. Dhaun N., Webb D.J. Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?. Hypertension 2010, 56:575-577.
8. Dunnwald L.K., Gralow J.R., Ellis G.K., Livingston R.B., Linden H.M., Specht J.M., Doot R.K., Lawton T.J., Barlow W.E., Kurland B.F., et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J.Clin. Oncol. 2008, 26:4449-4457.
9. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
10. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
11. Ferrara N., Hillan K.J., Gerber H.P., Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004, 3:391-400.
12. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer 2002, 2:683-693.
13. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
14. Griffon-Etienne G.E., Boucher Y., Brekken C., Suit H.D., Jain R.K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 1999, 59:3776-3782.
15. Gunn R.N., Sargent P.A., Bench C.J., Rabiner E.A., Osman S., Pike V.W., Hume S.P., Grasby P.M., Lammertsma A.A. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 1998, 8:426-440.
16. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
17. Hermansen F., Rosen S.D., Fath-Ordoubadi F., Kooner J.S., Clark J.C., Camici P.G., Lammertsma A.A. Measurement of myocardial blood flow with oxygen-15 labelled water: comparison of different administration protocols. Eur. J. Nucl. Med. 1998, 25:751-759.
18. Hoekstra C.J., Stroobants S.G., Hoekstra O.S., Smit E.F., Vansteenkiste J.F., Lammertsma A.A. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin. Cancer Res. 2002, 8:2109-2115.
19. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N.Engl. J. Med. 2004, 350:2335-2342.
20. Jackson J.R., Dembowski B.S., Ehrenkaufer R.L., McIntyre E., Reivich M. [15O]H2O, [15O]O2 and [15O]CO gas production, monitoring and quality control system. Appl. Radiat. Isot. 1993, 44:631-634.
21. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7:987-989.
22. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
23. Kamba T., Tam B.Y., Hashizume H., Haskell A., Sennino B., Mancuso M.R., Norberg S.M., O'Brien S.M., Davis R.B., Gowen L.C., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H560-H576.
24. Knaapen P., Lubberink M., Rijzewijk L.J., van der Meer R.W., Unger M., Germans T., Bax J.J., Smit J.W., Lamb H.J., van Rossum A.C., et al. Stroke volume measurements with first-pass dynamic positron emission tomography: comparison with cardiovascular magnetic resonance. J.Nucl. Cardiol. 2008, 15:218-224.
25. Kudoh S., Takeda K., Nakagawa K., Takada M., Katakami N., Matsui K., Shinkai T., Sawa T., Goto I., Semba H., et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J.Clin. Oncol. 2006, 24:3657-3663.
26. Lodge M.A., Carson R.E., Carrasquillo J.A., Whatley M., Libutti S.K., Bacharach S.L. Parametric images of blood flow in oncology PET studies using [15O]water. J.Nucl. Med. 2000, 41:1784-1792.
27. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N.Engl. J. Med. 2007, 357:2666-2676.
28. Mourad J.J., des Guetz G., Debbabi H., Levy B.I. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann. Oncol. 2008, 19:927-934.
29. Ng Q.S., Goh V., Milner J., Stratford M.R., Folkes L.K., Tozer G.M., Saunders M.I., Hoskin P.J. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol. 2007, 8:111-118.
30. Ortholan C., Durivault J., Hannoun-Levi J.M., Guyot M., Bourcier C., Ambrosetti D., Safe S., Pagès G. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment. Eur. J. Cancer 2010, 46:3022-3036.
31. Patlak C.S., Blasberg R.G., Fenstermacher J.D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J.Cereb. Blood Flow Metab. 1983, 3:1-7.
32. Reese D., Fratesi P., Corry M., Novotny W., Holmgren E., Small E. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. The Prostate J. 2001, 3:65-70.
33. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N.Engl. J. Med. 2006, 355:2542-2550.
34. Serné E.H., Gans R.O., ter Maaten J.C., Tangelder G.J., Donker A.J., Stehouwer C.D. Impaired skin capillary recruitment in essential hypertension is caused by both functional and structural capillary rarefaction. Hypertension 2001, 38:238-242.
35. Serné E.H., IJzerman R.G., Gans R.O., Nijveldt R., De Vries G., Evertz R., Donker A.J., Stehouwer C.D. Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia. Diabetes 2002, 51:1515-1522.
36. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., Daenen L.G., Man S., Xu P., Emmenegger U., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
37. Shalli K., Brown I., Heys S.D., Schofield A.C. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J. 2005, 19:1299-1301.
38. Surti S., Kuhn A., Werner M.E., Perkins A.E., Kolthammer J., Karp J.S. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J.Nucl. Med. 2007, 48:471-480.
39. Syrigos K.N., Karapanagiotou E., Boura P., Manegold C., Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 2011, 25:159-169.
40. van der Veldt A.A., Hendrikse N.H., Harms H.J., Comans E.F., Postmus P.E., Smit E.F., Lammertsma A.A., Lubberink M. Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J.Nucl. Med. 2010, 51:1684-1690.
41. Van der Veldt A.A., Hendrikse N.H., Smit E.F., Mooijer M.P., Rijnders A.Y., Gerritsen W.R., van der Hoeven J.J., Windhorst A.D., Lammertsma A.A., Lubberink M. Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:1950-1958.
42. Van der Veldt A.A., Lubberink M., Greuter H.N., Comans E.F., Herder G.J., Yaqub M., Schuit R.C., Van Lingen A., Rizvi S.N., Mooijer M.P., et al. Absolute quantification of [11C]docetaxel kinetics in lung cancer patients using positron emission tomography. Clin. Cancer Res. 2011, 15:4814-4824.
43. van Tilburg E.W., Franssen E.J., Van der Hoeven J.J., Van der Meij M., Elshove D., Lammertsma A.A., Windhorst A.D. Radiosynthesis of [11C]docetaxel. J.Labelled Comp. Rad. 2004, 47:763-777.
44. van Tilburg E.W., Mooijer M.P., Brinkhorst J., van der Meij M., Windhorst A.D. Improved and semi-automated GMP-compliant radiosynthesis of [11C]docetaxel. Appl. Radiat. Isot. 2008, 66:1414-1418.
45. Verheul H.M., Hoekman K., Luykx-de Bakker S., Eekman C.A., Folman C.C., Broxterman H.J., Pinedo H.M. Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 1997, 3:2187-2190.
46. Watabe H., Jino H., Kawachi N., Teramoto N., Hayashi T., Ohta Y., Iida H. Parametric imaging of myocardial blood flow with 15O-water and PET using the basis function method. J.Nucl. Med. 2005, 46:1219-1224.
47. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., Chung D.C., Sahani D.V., Kalva S.P., Kozin S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10:145-147.
48. Wilson C.B., Lammertsma A.A., McKenzie C.G., Sikora K., Jones T. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res. 1992, 52:1592-1597.
49. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N.Engl. J. Med. 2003, 349:427-434.